← Leaderboards
Marc G. Caron
Duke University
$32,189,154
Attributed
$37,595,210
Total exposure
27
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2005–21$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$51,552,350 · 29
By mechanism
U19$15,333,420 · 6
R01$13,709,251 · 5
P30$6,665,528 · 3
R37$6,398,419 · 1
UG3$3,588,880 · 1
P50$1,756,387 · 1
Top collaborators
- Bryan L Roth15 shared
- Jian Jin5 shared
- William C Wetsel5 shared
- Lawrence S. Barak1 shared
- Jeffrey T Guptill1 shared
- Michael Jackson1 shared
Most similar at Duke University
Same institution · by research overlap
- Robert J Lefkowitz$17,365,480
- William C Wetsel$2,175,976
- Jian Jin$14,335,932
- Walter J Koch$36,219,689
- Yuri Karl Peterson$1,356,896
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoSignal TransductionPharmaceutical PreparationsResponseBaseBehavioralBiochemicalPathway InteractionsReceptorG-Protein-Coupled ReceptorsDopamineLigandsSchizophreniaMediatingResearch PersonnelNovel StrategiesProgramsBehaviorSignal PathwayNeuronsMutantLeadBrainDrug Discovery
Grant awards (128)
Exploiting Dopamine Receptor Functional Selectivity as an Approach to Treat Parkinson's Symptoms$636,146
R01 · FY2021 · NS · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$650,556
R37 · FY2020 · MH · contact PI
Exploiting Dopamine Receptor Functional Selectivity as an Approach to Treat Parkinson's Symptoms$638,745
R01 · FY2020 · NS · contact PI
Development of SBI-553, an allosteric modulator of NTR1, for the treatment of substance use disorders$3,588,880
UG3 · FY2019 · DA
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$650,556
R37 · FY2019 · MH · contact PI
Exploiting Dopamine Receptor Functional Selectivity as an Approach to Treat Parkinson's Symptoms$641,290
R01 · FY2019 · NS · contact PI
Simultaneous and Bidirectional Chemogenetic Control of Mesolimbic and Nigrostriatal Circuits$200,833
R21 · FY2019 · MH · contact PI
Unmasking a Role for Cortical Dopamine D4 Receptors in Controlling Circuit Dynamics and Behavior$197,691
R21 · FY2019 · MH · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$650,556
R37 · FY2018 · MH · contact PI
Exploiting Dopamine Receptor Functional Selectivity as an Approach to Treat Parkinson's Symptoms$643,836
R01 · FY2018 · NS · contact PI
Drug Abuse: Discovering Ligands for Pertinent GPCRs$627,017
P30 · FY2018 · DA · contact PI
Simultaneous and Bidirectional Chemogenetic Control of Mesolimbic and Nigrostriatal Circuits$239,625
R21 · FY2018 · MH · contact PI
Unmasking a Role for Cortical Dopamine D4 Receptors in Controlling Circuit Dynamics and Behavior$197,295
R21 · FY2018 · MH · contact PI
Drug Abuse: Discovering Ligands for Pertinent GPCRs$158,837
P30 · FY2018 · DA · contact PI
Exploiting Dopamine Receptor Functional Selectivity as an Approach to Treat Parkinson's Symptoms$661,206
R01 · FY2017 · NS · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$650,556
R37 · FY2017 · MH · contact PI
Drug Abuse: Discovering Ligands for Pertinent GPCRs$640,139
P30 · FY2017 · DA · contact PI
A Cancer Rainbow Mouse for Simultaneous Assessment of Multiple Oncogenes$393,463
R33 · FY2017 · CA · contact PI
Drug Abuse: Discovering Ligands for Pertinent GPCRs$98,375
P30 · FY2017 · DA · contact PI
Functional Selectivity: A Novel Approach for CNS Drug Discovery$1,527,521
U19 · FY2016 · MH
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$644,733
R37 · FY2016 · MH · contact PI
Drug Abuse: Discovering Ligands for Pertinent GPCRs$642,616
P30 · FY2016 · DA · contact PI
Behavioral Core$397,637
U19 · FY2016 · MH
A Cancer Rainbow Mouse for Simultaneous Assessment of Multiple Oncogenes$395,912
R33 · FY2016 · CA · contact PI
The 5-HT theory of depression tested in a naturalistic model of 5-HT deficiency$392,500
R01 · FY2016 · MH · contact PI
Project 2$373,252
U19 · FY2016 · MH · contact PI
Chemistry Project$342,000
U19 · FY2016 · MH
Screening Core$284,825
U19 · FY2016 · MH
Administrative Core$41,829
U19 · FY2016 · MH
Functional Selectivity: A Novel Approach for CNS Drug Discovery$1,527,521
U19 · FY2015 · MH
Drug Abuse: Discovering Ligands for Pertinent GPCRs$642,037
P30 · FY2015 · DA · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$586,469
R37 · FY2015 · MH · contact PI
Project 2$461,230
U19 · FY2015 · MH · contact PI
Behavioral Core$397,637
U19 · FY2015 · MH
The 5-HT theory of depression tested in a naturalistic model of 5-HT deficiency$392,500
R01 · FY2015 · MH · contact PI
A Cancer Rainbow Mouse for Simultaneous Assessment of Multiple Oncogenes$389,963
R33 · FY2015 · CA · contact PI
Chemistry Project$342,000
U19 · FY2015 · MH
Screening Core$284,825
U19 · FY2015 · MH
Administrative Core$41,829
U19 · FY2015 · MH
Functional Selectivity: A Novel Approach for CNS Drug Discovery$1,527,521
U19 · FY2014 · MH
Drug Abuse: Discovering Ligands for Pertinent GPCRs$660,956
P30 · FY2014 · DA · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$589,795
R37 · FY2014 · MH · contact PI
Project 2$461,230
U19 · FY2014 · MH · contact PI
Behavioral Core$397,637
U19 · FY2014 · MH
The 5-HT theory of depression tested in a naturalistic model of 5-HT deficiency$392,500
R01 · FY2014 · MH · contact PI
Chemistry Project$342,000
U19 · FY2014 · MH
Screening Core$284,825
U19 · FY2014 · MH
Drug Abuse: Discovering Ligands for Pertinent GPCRs$131,794
P30 · FY2014 · DA · contact PI
The 5-HT theory of depression tested in a naturalistic model of 5-HT deficiency$100,000
R01 · FY2014 · MH · contact PI
Cell Regulation$52,657
P30 · FY2014 · CA · contact PI
Administrative Core$41,829
U19 · FY2014 · MH
Functional Selectivity: A Novel Approach for CNS Drug Discovery$1,466,420
U19 · FY2013 · MH
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$692,395
R37 · FY2013 · MH · contact PI
Drug Abuse: Discovering Ligands for Pertinent GPCRs$615,920
P30 · FY2013 · DA · contact PI
Project 2$442,780
U19 · FY2013 · MH · contact PI
Behavioral Core$381,732
U19 · FY2013 · MH
The 5-HT theory of depression tested in a naturalistic model of 5-HT deficiency$366,677
R01 · FY2013 · MH · contact PI
Chemistry Project$328,319
U19 · FY2013 · MH
Screening Core$273,432
U19 · FY2013 · MH
A Cancer Rainbow Mouse for the Simultaneous Assessment of Multiple Oncogenes$240,536
R21 · FY2013 · CA · contact PI
Administrative Core$40,157
U19 · FY2013 · MH
Cell Regulation$33,152
P30 · FY2013 · CA · contact PI
Functional Selectivity: A Novel Approach for CNS Drug Discovery$1,661,716
U19 · FY2012 · MH
Drug Abuse: Discovering Ligands for Pertinent GPCRs$658,551
P30 · FY2012 · DA · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$600,491
R37 · FY2012 · MH · contact PI
Behavioral Core$463,329
U19 · FY2012 · MH
Project 2$455,437
U19 · FY2012 · MH · contact PI
The 5-HT theory of depression tested in a naturalistic model of 5-HT deficiency$392,500
R01 · FY2012 · MH · contact PI
Chemistry Project$380,000
U19 · FY2012 · MH
Screening Core$316,473
U19 · FY2012 · MH
A Cancer Rainbow Mouse for the Simultaneous Assessment of Multiple Oncogenes$235,546
R21 · FY2012 · CA · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$61,026
R37 · FY2012 · MH · contact PI
Administrative Core$46,477
U19 · FY2012 · MH
Cell Regulation$36,343
P30 · FY2012 · CA · contact PI
Cell Regulation$2,501
P30 · FY2012 · CA · contact PI
Drug Abuse: Discovering Ligands for Pertinent GPCRs$673,672
P30 · FY2011 · DA · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$621,286
R37 · FY2011 · MH · contact PI
Functional Variants of the Human TPH2 Gene$334,491
R01 · FY2011 · MH · contact PI
Drug Abuse: Discovering Ligands for Pertinent GPCRs$153,860
P30 · FY2011 · DA · contact PI
Cell Regulation$37,987
P30 · FY2011 · CA · contact PI
Drug Abuse: Discovering Ligands for Pertinent GPCRs$542,667
P30 · FY2010 · DA · contact PI
Functional Variants of the Human TPH2 Gene$387,350
R01 · FY2010 · MH · contact PI
Mouse Models, KOs, Transgenics, and Gene Expression Monoamine Systems$345,524
P50 · FY2010 · MH · contact PI
Management/Administrative Plan$214,771
P30 · FY2010 · DA · contact PI
STRIATAL NEUROANATOMY IN DOPAMINE TRANSPORTER KNOCKOUT MICE$43,032
P41 · FY2010 · RR · contact PI
Cell Regulation$41,676
P30 · FY2010 · CA · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$434,634
R01 · FY2009 · MH · contact PI
Mouse Models, KOs, Transgenics, and Gene Expression Monoamine Systems$349,904
P50 · FY2009 · MH · contact PI
Functional Variants of the Human TPH2 Gene$312,000
R01 · FY2009 · MH · contact PI
STRIATAL NEUROANATOMY IN DOPAMINE TRANSPORTER KNOCKOUT MICE$56,103
P41 · FY2009 · RR · contact PI
Functional Variants of the Human TPH2 Gene$48,770
R01 · FY2009 · MH · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$421,975
R01 · FY2008 · MH · contact PI
Drug abuse: Discovering ligands for pertinent GPCRs$371,116
U01 · FY2008 · DA · contact PI
Mouse Models, KOs, Transgenics, and Gene Expression Monoamine Systems$348,547
P50 · FY2008 · MH · contact PI
Functional Variants of the Human TPH2 Gene$312,000
R01 · FY2008 · MH · contact PI
STRIATAL NEUROANATOMY IN DOPAMINE TRANSPORTER KNOCKOUT MICE$35,121
P41 · FY2008 · RR · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$421,920
R01 · FY2007 · MH · contact PI
Drug abuse: Discovering ligands for pertinent GPCRs$400,246
U01 · FY2007 · DA · contact PI
Mouse Models, KOs, Transgenics, and Gene Expression Monoamine Systems$360,530
P50 · FY2007 · MH · contact PI
Dopamine Receptors: Characterization and Regulation$337,671
R01 · FY2007 · NS · contact PI
Functional Variants of the Human TPH2 Gene$311,416
R01 · FY2007 · MH · contact PI
Elucidating the actions of acetylcholine in the brain$38,231
R03 · FY2007 · TW · contact PI
STRIATAL NEUROANATOMY IN DOPAMINE TRANSPORTER KNOCKOUT MICE$37,985
P41 · FY2007 · RR · contact PI
Drug abuse: Discovering ligands for pertinent GPCRs$474,875
U01 · FY2006 · DA · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$421,866
R01 · FY2006 · MH · contact PI
Mouse Models, KOs, Transgenics, and Gene Expression Monoamine Systems$351,882
P50 · FY2006 · MH · contact PI
Dopamine Receptors: Characterization and Regulation$347,757
R01 · FY2006 · NS · contact PI
Elucidating the actions of acetylcholine in the brain$39,372
R03 · FY2006 · TW · contact PI
STRIATAL NEUROANATOMY IN DOPAMINE TRANSPORTER KNOCKOUT MICE$35,603
P41 · FY2006 · RR · contact PI
Akt/GSK-3 Signaling Cascade and the Actions of Dopamine$419,434
R01 · FY2005 · MH
Dopamine Receptors: Characterization and Regulation$356,125
R01 · FY2005 · NS
GENETIC ANALYSIS OF DOPAMINERGIC REWARD MECHANISMS$154,000
R01 · FY2005 · DA
Elucidating the actions of acetylcholine in the brain$40,320
R03 · FY2005 · TW
STRIATAL NEUROANATOMY IN DOPAMINE TRANSPORTER KNOCKOUT MICE$11,884
P41 · FY2005 · RR
Dopamine Receptors: Characterization and Regulation$356,125
R01 · FY2004 · NS
GENETIC ANALYSIS OF DOPAMINERGIC REWARD MECHANISMS$324,597
R01 · FY2004 · DA
STRIATAL NEUROANATOMY/DOPAMINE TRANSPORTER KNOCKOUT MICE$25,713
P41 · FY2004 · RR
DOPAMINE RECEPTORS--CHARACTERIZATION AND REGULATION$341,007
R01 · FY2003 · NS
GENETIC ANALYSIS OF DOPAMINERGIC REWARD MECHANISMS$315,144
R01 · FY2003 · DA
DOPAMINE RECEPTORS--CHARACTERIZATION AND REGULATION$331,075
R01 · FY2002 · NS
GENETIC ANALYSIS OF DOPAMINERGIC REWARD MECHANISMS$305,965
R01 · FY2002 · DA
GENETIC DISTRUPTION OF MONOAMINE SYSTEMS: IMPLICATION FOR DEPRESSION$0
P50 · FY2002 · MH
DOPAMINE RECEPTORS--CHARACTERIZATION AND REGULATION$376,152
R01 · FY2001 · NS
GENETIC ANALYSIS OF DOPAMINERGIC REWARD MECHANISMS$297,053
R01 · FY2001 · DA
GENETIC DISTRUPTION OF MONOAMINE SYSTEMS: IMPLICATION FOR DEPRESSION$0
P50 · FY2001 · MH
GENETIC ANALYSIS OF DOPAMINERGIC REWARD MECHANISMS$367,781
R01 · FY2000 · DA
DOPAMINE RECEPTORS--CHARACTERIZATION AND REGULATION$365,043
R01 · FY2000 · NS
DOPAMINE RECEPTORS--CHARACTERIZATION AND REGULATION$50,000
R01 · FY2000 · NS